Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chuanpu Hu

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|November 26, 2004
Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjectsChuanpu Hu, Katy H P Moore, Yong H Kim, et al.
Clinical Pharmacology and Therapeutics|November 9, 2023
No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and CostVincent Lemaire, Chuanpu Hu, Piet H van der Graaf, et al.
Journal of Clinical Pharmacology|July 13, 2010
Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritisChuanpu Hu, Zhenhua Xu, Yi Zhang, et al.
Journal of Clinical Pharmacology|June 15, 2018
Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid ArthritisYan Xu, Chuanpu Hu, Yanli Zhuang, et al.
Journal of Clinical Pharmacology|November 26, 2009
Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasisHonghui Zhou, Chuanpu Hu, Yaowei Zhu, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 23, 2026
Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood FrameworkShengnan Du, Jessica Wojciechowski, Peijin Zhang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 18, 2018
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasisChuanpu Hu, Zhenling Yao, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque PsoriasisWangda Zhou, Chuanpu Hu, Yaowei Zhu, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Journal of Pharmacokinetics and Pharmacodynamics|November 26, 2004
Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjectsChuanpu Hu, Katy H P Moore, Yong H Kim, et al.
Clinical Pharmacology and Therapeutics|November 9, 2023
No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and CostVincent Lemaire, Chuanpu Hu, Piet H van der Graaf, et al.
Journal of Clinical Pharmacology|July 13, 2010
Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritisChuanpu Hu, Zhenhua Xu, Yi Zhang, et al.
Journal of Clinical Pharmacology|June 15, 2018
Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid ArthritisYan Xu, Chuanpu Hu, Yanli Zhuang, et al.
Journal of Clinical Pharmacology|November 26, 2009
Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasisHonghui Zhou, Chuanpu Hu, Yaowei Zhu, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 23, 2026
Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood FrameworkShengnan Du, Jessica Wojciechowski, Peijin Zhang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 18, 2018
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasisChuanpu Hu, Zhenling Yao, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque PsoriasisWangda Zhou, Chuanpu Hu, Yaowei Zhu, et al.
Pageof 6